Reddit Posts
IOBT -- $11 price target by H.C. Wainwright
Mentions
Why IOBT is in hype can someone explain?
What’s catalyst with IOBT?
IOBT buy the dip the had positive research news
IOBT GET IN we going up 🚀🚀🚀
IOBT stock price EOD is around 1.60 nice point to.get in
$IOBT the next $RANI - amazing news!
Loaded up on $IOBT things going to clear a dollar today
And after do you think IOBT can do more?
The fact that IOBT has been flying under the radar quietly building momentum, and most importantly nobody was spamming the shit outta it was exactly why I got in last week at .5. This is the way 🙏
IOBT will have a run right up to 9:30. great chance for a short, quick profit
IOBT I0 Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma
Man I’m so fing green today up 10k and haven’t even made coffee yet lol 🥰 DVLT NUAI IOBT OPEN GPUS VIVk
Swing on IOBT for me today. Other than that just going to let it ride, see yall Tuesday ✌️
Bad day for many tickers but not IOBT
I went in IOBT. Another bio stock. Bought in sub 1.00. Price targets were 9.00. And then one day I wake up and they missed one of their targets and laid off half their workforce. Don't get super caught up in analysts and price targets.
So much plays for today $IOBT, $DFLI, $BURU, $LPTX
Let's see how $IOBT, $DFLI, $BURU, $LPTX plays let's go
does anyone know why IOBT dropped a bunch
Thoughts on IOBT? At its 52-week low
IOBT Thoughts after yesterday’s dip?
Got ATCH at 0.7. It better touch $1 after the filing, otherwise I’m screwed. Took 2 bad hits today with IOBT and WOLF — both down 80%.
There’s so many to choose from - game time decision Monday to go w IOBT, RZLV or NRXP…good luck everyone!
So no for both because MBRX is a long way from approval and are already in a cash crunch, so most likely alot more dilution. IOBT has major cash issues as they will prob have to raise cash even before they submit the NDA (they say cash into 1Q 2026, approval at the earliest would be 4Q 2026), plus the trial narrowly missed its goal, which could cause issues with getting approval.
When is IOBT's EoP3 meeting with the FDA?
IOBT did after a similar drop. I'm solidly convinced people (not institutions) buy on hint of news coming. They will have more updates on their great drug, maybe a merger? Maybe a buy out? In the end, it will climb on FOMO at these levels. Slow but it will come back.
$IOBT for example. Dropped hard on news last week. Now up .30 and they announced crap earnings. Strange.
BTAI - please be careful, let’s hope it does not be the same as IOBT.
It’s just got me out of a $300 dollar bag I’ve been holding since it last spiked and I fomo’d in at 2.04. Just managed to get out at 2.18 with a little profit too! Thank you IOBT
IOBT is rolling. Looking for 2.50
It would be interesting to see IOBT make the same jump as it did last week.
Curious who else is looking at IOBT. I'm new to watching pharma stocks, and just am curious to hear what others think for pros/cons.
Do you feel IOBT will be a good one to get into before their main dates next week as well?
Are we interested in IOBT for next week? Seems like a good one
IOBT today...I did some swing today!
IOBT is back in the game, predictions about today's earnings?
I really thought I did something with IOBT circa 7:53 ET this morning
Totally. Just loaded up more on $IOBT, definitely worth a watch 🐂
Anyone on IOBT was supposed to sell pre market. It was a pump and dump, everyone in on that stock knew this
here’s where my head’s at for aug/early sept (dates move, so DYOR): keeping an eye on IOBT after the topline P3 in melanoma, want to see follow-ups on durability/OS, plus any partner chatter and how they handle financing; CYTK for late-stage cardiomyopathy and how they pace the reg/launch story; VKTX across obesity/NASH where study design and tolerability matter more to me than headline hype; IMTX on TCR/T-cell durability and the exact wording around the registrational path; IOVA where it’s all about commercial execution and label expansions now; and SGMT as a mid-to-late NASH name where runway and phase-transition risk are front and center. i’ve been cleaning watchlists, re-reading protocols/SAPs, and tagging spots where label language could be the swing factor. also journaling each idea with simple if/then exits (e.g., approval + boxed warning = fade. clean label + no REMS = consider holding into early launch metrics). Not advice, just sharing how i’m approaching it. if you’re tracking other late-stage names or a weird PDUFA setup this month, drop it below and let’s sanity-check together.
I bought the IOBT dip… I regret my actions
let's see if IOBT can find a bottom...
Do we think IOBT is a good buy at the dip?
https://www.stocktitan.net/news/IOBT/io-biotech-announces-clinical-improvement-in-progression-free-m6ole6grct3e.html
IOBT dip. Would be great if it was a runner today.
Made $200 on IOBT. THANKS GUYS
IOBT primary endpoints were just barely missed
Was up 50% on IOBT, halted, halt ceased and I’m now at 15% loss within a second. Can’t make this shit up
Awesome IOBT, I appreciate that 😒
IOBT plummeting even with rumoured good news about Phase 2 Results?, Of course it'll bottom once I buy some shares
IOBT may blow with the phase 3 results today at 8:30 am! https://www.stocktitan.net/news/IOBT/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-smndfr3pdv2n.html
$IOBT announcing phase 3 results from their cancer drug at 8:30 ET. Looking good.
I came back to this post to add this update too hahahaha. Thanks for posting in the r/IOBT thread 🫡
I know my move tomorrow. I'm going to watch the $IOBT live call premarket. Then if phase 3 results are successful, I'll be happy. If they are terrible, I'm going to be inconsolable.
!banbet IOBT 6 8w or I'll wash my hair in pasta sauce.
Ticker $IOBT. It is traded on the Nasdaq. You buy it where you'd buy any stock.
$IOBT up 73% last month and 20% today…slowly been rising for a while now, with no news, this is a clear sign of a buyout. I’d get in and not make the mistake I did with $RGLS…
Bought some IOBT to try to catch the wave.
Just got in on IOBT. Looks like it has lots of room to run with some buying pressure.
IOBT up 10% today but no news on their clinical trials. Interesting.
IOBT is like an earlier stage European IOVA with a huge credit line from the European Investment Bank, a stage 3 clinical trial due this quarter and a less crowded trade gonna be honest. Partnership with Merck, too.
IOBT (biotech) or ABAT (critical materials). \*finger guns\*
Take a look at IOBT, and google it alongside its EIB backing / phase 3 results for a moonshot. CADL looks good too but its more mature (pre-approval). I have positions in both. CRISPR I feel like I missed the boat on?
IOBT & CADL both look good too me.
Thanks for the post. I wish more people talked about pharma plays on here. I know it’s a bit of a gamble—I was in LXRX for the past few weeks and sold at the overreaction for a major loss to make other plays, but LXRX is still solid. Wish I just doubled down. Going to look into IOBT!
Biotech - IOBT and CLLS today should have news on preclinical and clinical trial data etc.
Watching my IOBT, HOLO, and WNW today, fingers crossed for a good day. Good luck yall!
looking at IOBT and ATCH
IOBT , WIMI, TLRY low risk high reward. Just buy 100 shares and forget about them
Yes, Will look into IOBT too, I've been analyzing biotech companies with great potentials
IOBT if you talking about MYNZ. IOBT developing cancer vaccines. But I will wait for stage 4 result
IOBT. No position in it yet it’s really caught my eye. And for the record, I am more gambler than investor. Lol
Assessing the likelihood of IO Biotech’s (IOBT) stock rising in percentage terms involves analyzing its clinical, financial, and market conditions: Analyst Expectations • Consensus Upside: Analysts have a 12-month average price target of $9.33, with high estimates at $12. This implies a potential upside of 1,081%–1,249% based on current prices   . • Market Sentiment: The stock has received consistent “Buy” ratings from analysts, and their forecasts rely on IO Biotech’s clinical progress and financial stability. The high upside reflects speculative potential but hinges heavily on clinical trial results. Clinical Progress Impact • The Phase 3 melanoma trial and Phase 2 studies for other cancers show strong potential. Positive outcomes could lead to significant market valuation increases. However, biotech stocks are inherently risky, with success rates for drugs in Phase 3 trials typically around 50%-60% industry-wide. Risks • While the upside is substantial, any negative trial results or delays could sharply reduce stock value. The biotech sector is volatile, and IOBT’s reliance on one primary product in trials amplifies the risk. Probability of Success Given the strong clinical data and sufficient funding into 2025, coupled with analyst optimism, the stock has a 60%-70% probability of achieving a significant rise in the short term (next 1–2 years). However, this probability should be weighed against the inherent risks of drug development and market dynamics.
If you don’t know much about stocks, I don’t think penny stocks are a good place to start. In my opinion, it’s a lot of risk and if you don’t know what you’re doing you could end up losing your whole account. Definitely don’t trade penny stocks with money you can’t afford to lose. Some examples of small cap (low market cap) runners recently are GLMD, BBLG, SMSI, BFI and IOBT. Again, things sometimes randomly pump, so just because something spiked once doesn’t mean it will again. You don’t have to take my advice, it’s just what I recommend. Best of luck!
Bought 10,000 shares of IOBT just before close today (@$1.47). Tomorrow I just sit and watch my holdings... hope for green and not red...
IOBT -- Just got $11 price target (over 500% upside) -- [https://finance.yahoo.com/news/2-strong-buy-penny-stocks-135524414.html](https://finance.yahoo.com/news/2-strong-buy-penny-stocks-135524414.html)